GlaxoSmithKline is recalling supplies of its OTC weight-loss drug alli in light of reports from U.S. consumers who found the wrong drug when they opened their bottles.
Drug tampering not only poses threats to consumers but is also disruptive and expensive for drugmakers. In the latest case, GlaxoSmithKline sent out an alert Wednesday warning that someone has been altering its over-the-counter weight-loss drug alli.
GlaxoSmithKline announced today that bottles of its alli over-the-counter weight-loss drug were tampered with, and warned consumers to look out for suspect packages.
Some U.S. consumers found the wrong drug when they opened their packages of alli, the GlaxoSmithKline weight-loss pill, the company said. Glaxo is warning alli users to check their packages carefully and avoid taking any pills that might not be authentic.
GlaxoSmithKline has buyers interested in taking the diet drug Alli off its hands, if Roche could just get its manufacturing issues fixed.
GlaxoSmithKline's ($GSK) good news: It has found a buyer for European rights to a portfolio of consumer products it has been trying to unload for some time. The not-so-good: It's still stuck with Alli, the weight-loss drug, as supply problems weigh on its ability to market the brand.
Omega Pharma will get GlaxoSmithKline's ($GSK) manufacturing plant in Herrenberg, Germany, as part of the $612 million acquisition of GSK's over-the-counter healthcare brands in Europe.
GlaxoSmithKline ($GSK) wants to make a deal already. After hawking a portfolio of consumer drugs for months, the company managed to unload 17 of them to Prestige Brands Holdings in December. Now, it
GlaxoSmithKline ($GSK) can thank Greece and Angela Merkel if its attempt to sell an OTC drug portfolio stalls. Europe's inability to get its act together is frustrating some M&A, as satisfactory
Shengyang Zhou, of Yunnan, China, has been given 87 months in federal prison and fined more than $500,000. Zhou pleaded guilty in January to trafficking and importing counterfeit Alli, the